Radnor Capital Management’s Edwards Lifesciences EW Stock Holding History

Radnor Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43M	Hold	26,915	–	–	0.34%	77
2026 Q1	$2.16M	Hold	26,915	–	–	0.32%	84
2025 Q4	$2.29M	Sell	26,915 -175	-0.6%	-$14.4K	0.34%	84
2025 Q3	$2.11M	Hold	27,090	–	–	0.32%	91
2025 Q2	$2.12M	Buy	27,090 +3,020	+13%	+$225K	0.34%	77
2025 Q1	$1.75M	Buy	24,070 +2,400	+11%	+$172K	0.29%	91
2024 Q4	$1.6M	Sell	21,670 -2,114	-9%	-$148K	0.27%	98
2024 Q3	$1.57M	Buy	23,784 +18,600	+359%	+$1.35M	0.23%	114
2024 Q2	$479K	Hold	5,184	–	–	0.15%	113
2024 Q1	$495K	Hold	5,184	–	–	0.08%	220
2023 Q4	$395K	Sell	5,184 -600	-10%	-$41.7K	0.07%	240
2023 Q3	$401K	Hold	5,784	–	–	0.08%	234
2023 Q2	$546K	Buy	+5,784	New	+$503K	0.23%	83

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Radnor Capital Management's EW Position: Q2 2026 in Review

Radnor Capital Management held its Edwards Lifesciences (EW) position steady in Q2 2026 at 26,915 shares worth $2.43M. The position accounts for 0.34% of the portfolio, ranked #77.

Radnor Capital Management first reported a position in EW in Q2 2023 and has held it in 13 quarters since. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Radnor Capital Management held 26,915 shares of Edwards Lifesciences worth $2.43M as of Q2 2026.
Radnor Capital Management left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.34% of Radnor Capital Management's portfolio in Q2 2026, its #77 holding.
Radnor Capital Management first reported a position in Edwards Lifesciences in Q2 2023 and has held it in 13 quarters since.
1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Radnor Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.